Merck Stock Holds Firm Above Key Levels After FDA Accepts RSV Filing

Merck's stock has held above key technical levels after the FDA accepted its filing for an RSV disease treatment. The company's stock price currently stands at $128.34, with a market value of near $308.9 billion and employing over 73,000 people.

The acceptance of Merck's regulatory filing marks a significant milestone in the company's drug pipeline. The stock has displayed a bullish technical outlook, with a 75% probability of upside and an expected trading range of $125.99 to $130.68 for the coming week.

While the timing of the regulatory headline cannot be directly linked to the market move, traders are monitoring intraday price action for confirmation around the recent range. A close above $131.47 would indicate buyers pushing the narrative forward, while a drop below $127.61 would suggest the move is being faded.

Merck's technical setup remains broadly bullish, with price action guided by support at key moving averages. The latest regulatory milestone adds new dimension to the story, and short-term traders should monitor whether a move through $131.47 confirms upside momentum in the coming week.